News 25.10.2024 The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO to pursue new professional challenges. Since taking on the role in 2023, Mr. Brenneisen has made significant progress in guiding the company toward a future-oriented strategy and fostering a cultural change in preparation...
News 25.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...
News 24.10.2024 Zurich, Switzerland - 23.10.2024 Neurimmune today announced that the translational PK/PD model relating to the human antibody ALXN2220 (formerly NI006) have been published in the current issue of Clinical Pharmacology & Therapeutics. The manuscript “Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK/PD modeling” describes the mechanistic pharmacokinetic and pharmacodynamic...
News 23.10.2024 Using a new method, researchers at ETH Zurich can measure alterations in the social network of proteins in cells. This work lays the foundation for the development of new drugs to treat diseases such as cancer and Alzheimer’s. Inside cells, it's like in a packed dance club: hundreds are partying. Some...
News 22.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical...